DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,962 | +11.2% | 7,915 | +7.6% | 0.01% | +14.3% |
Q2 2023 | $1,764 | -46.6% | 7,357 | -43.9% | 0.01% | -50.0% |
Q1 2023 | $3,304 | +18.5% | 13,114 | +24.8% | 0.01% | 0.0% |
Q4 2022 | $2,789 | -99.9% | 10,512 | +26.4% | 0.01% | +16.7% |
Q3 2022 | $2,147,000 | +17.3% | 8,319 | +15.3% | 0.01% | +33.3% |
Q2 2022 | $1,830,000 | -38.2% | 7,218 | -28.5% | 0.01% | -25.0% |
Q1 2022 | $2,960,000 | -40.9% | 10,099 | -33.7% | 0.01% | -36.8% |
Q4 2021 | $5,008,000 | -73.7% | 15,239 | -75.7% | 0.02% | -74.0% |
Q3 2021 | $19,069,000 | -46.8% | 62,687 | -53.0% | 0.07% | -45.9% |
Q2 2021 | $35,824,000 | +15.5% | 133,497 | -3.1% | 0.14% | +11.6% |
Q1 2021 | $31,020,000 | +6.9% | 137,829 | +5.5% | 0.12% | +8.0% |
Q4 2020 | $29,014,000 | -52.8% | 130,615 | -54.2% | 0.11% | -56.6% |
Q3 2020 | $61,472,000 | +4.6% | 285,485 | -14.1% | 0.26% | +2.0% |
Q2 2020 | $58,742,000 | +14.0% | 332,175 | -10.8% | 0.25% | -14.2% |
Q1 2020 | $51,526,000 | -28.0% | 372,297 | -20.2% | 0.30% | -9.2% |
Q4 2019 | $71,586,000 | -22.6% | 466,423 | -27.2% | 0.32% | -17.7% |
Q3 2019 | $92,535,000 | -10.9% | 640,709 | -11.8% | 0.40% | -20.7% |
Q2 2019 | $103,845,000 | -7.7% | 726,591 | -14.8% | 0.50% | +2.7% |
Q1 2019 | $112,526,000 | +22.3% | 852,337 | -4.5% | 0.48% | +6.4% |
Q4 2018 | $92,002,000 | -30.6% | 892,200 | -26.9% | 0.46% | -16.8% |
Q3 2018 | $132,598,000 | -5.0% | 1,220,299 | -13.7% | 0.55% | -9.1% |
Q2 2018 | $139,568,000 | -3.2% | 1,414,345 | -3.9% | 0.60% | -3.4% |
Q1 2018 | $144,172,000 | +5.8% | 1,472,504 | +0.3% | 0.62% | +5.6% |
Q4 2017 | $136,281,000 | +6.1% | 1,468,258 | -2.0% | 0.59% | +4.0% |
Q3 2017 | $128,492,000 | +2.1% | 1,497,882 | +0.5% | 0.57% | -0.4% |
Q2 2017 | $125,838,000 | +37.7% | 1,491,125 | +39.6% | 0.57% | +36.0% |
Q1 2017 | $91,379,000 | +173.7% | 1,068,378 | +149.1% | 0.42% | +158.6% |
Q4 2016 | $33,386,000 | +488.0% | 428,930 | +492.3% | 0.16% | +478.6% |
Q3 2016 | $5,678,000 | -3.3% | 72,421 | +24.5% | 0.03% | -6.7% |
Q2 2016 | $5,874,000 | -12.9% | 58,159 | -18.2% | 0.03% | -11.8% |
Q1 2016 | $6,741,000 | – | 71,058 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |